July 24 (Bloomberg) -- Aspen Pharmacare Holdings Ltd. offered GlaxoSmithKline Plc about 700 million pounds ($1.1 billion) for branded heart medicines Arixtra and Fraxiparine and a related manufacturing site.
The price includes about 100 million pounds for inventory and talks haven’t finished, Johannesburg-based Aspen said in a statement today. Glaxo said June 18 it got a bid from Aspen for the treatments.
Arixtra and Fraxiparine are part of a portfolio of more than 50 older products that Glaxo has carved out into a separate unit. The two drugs generated about 420 million pounds in global revenue in 2012 compared with 510 million pounds the previous year, Simon Steel, a spokesman for London-based Glaxo, said by phone June 18. The sale would exclude rights in China, India and Pakistan.
Aspen shares rose 2 percent to close at 219.60 rand in Johannesburg, the biggest gain in a week. Glaxo closed 0.5 percent higher at 1,681 pence in London.
The U.K.’s biggest pharmaceutical company, based in Brentford, owns a 19 percent stake in Aspen, a maker and distributor of generic medicines. Aspen agreed to buy pharmaceutical and over-the-counter brands from Glaxo in two separate transactions last year.
To contact the reporter on this story: Janice Kew in Johannesburg at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com